Temozolomide Salvage Chemotherapy for Recurrent Anaplastic Oligodendroglioma and Oligo-Astrocytoma

• Published in: Journal of Korean Neurosurgical Society 2013, Vol.54 (6), p.489-495
• Main Authors: Gwak, Ho-Shin, Yee, Gi Taek, Park, Chul-Kee, Kim, Jin Wook, Hong, Yong-Kil, Kang, Seok-Gu, Kim, Jeong Hoon, Seol, Ho Jun, Jung, Tae-Young, Chang, Jong Hee, Yoo, Heon, Hwang, Jeong-Hyun, Kim, Se-Hyuk, Park, Bong Jin, Hwang, Sun-Chul, Kim, Min Su, Kim, Seon-Hwan, Kim, Eun-Young, Kim, Ealmaan, Kim, Hae Yu, Ko, Young-Cho, Yun, Hwan Jung, Youn, Ji Hye, Kim, Juyoung, Lee, Byeongil, Lee, Seung Hoon
• Format: Article
• Language: Korean
• ISSN: 2005-3711; 1598-7876

Objective : To evaluate the efficacy of temozolomide (TMZ) chemotherapy for recurrent anaplastic oligodendroglioma (AO) and anaplastic oligoastrocytoma (AOA). Methods : A multi-center retrospective trial enrolled seventy-two patients with histologically proven AO/AOA who underwent TMZ chemotherapy for their recurrent tumors from 2006 to 2010. TMZ was administered orally (150 to 200 $mg/m^2/day$) for 5 days per 28 days until unacceptable toxicity occurred or tumor progression was observed. Results : TMZ chemotherapy cycles administered was median 5.3 (range, 1-41). The objective response rate was 24% including 8 cases (11%) of complete response and another 23 patients (32%) were remained as stable disease. Severe side effects (${\geq}$grade 3) occurred only in 9 patients (13%). Progression-free survival (PFS) of all patients was a median 8.0 months (95% confidence interval, 6.0-10.0). The time to recurrence of a year or after was a favorable prognostic factor for PFS (p